.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Farmers Insurance
Boehringer Ingelheim
Fuji
QuintilesIMS
Cipla
Covington
Citi
Chubb
Harvard Business School

Generated: November 19, 2017

DrugPatentWatch Database Preview

XELODA Drug Profile

« Back to Dashboard

Which patents cover Xeloda, and when can generic versions of Xeloda launch?

Xeloda is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in XELODA is capecitabine. There are twenty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.

Pharmacology for XELODA

Medical Subject Heading (MeSH) Categories for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-001Apr 30, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-001Apr 30, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-001Apr 30, 1998► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-001Apr 30, 1998► Subscribe► Subscribe
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896-002Apr 30, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for XELODA

Drugname Dosage Strength RLD Submissiondate
capecitabineTablets150 mg and 500 mgXeloda11/10/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Colorcon
Moodys
Chubb
Daiichi Sankyo
Novartis
Farmers Insurance
Cantor Fitzgerald
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot